ET
ETTYF.US Essity AB (publ)
- Market cap
- USD 18.7B
- P/E
- 16.0x
- P/B
- 1.90x
- ROE
- 10.6%
- Dividend yield
- 3.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ETTYF.US undervalued?
Graham numberETTYF.US trades 16.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Essity AB (publ) fundamental analysis
No fundamental analysis for Essity AB (publ) yet.
Essity AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Essity AB (publ)
Essity AB (publ) develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally. The company operates through three segments: Health & Medical, Consumer Goods, and Professional Hygiene. The Health & Medical segment offers incontinence products, wound care, compression therapy, orthopedics, skincare products, and digital solutions with sensor technology under the TENA, Leukoplast, JOBST, Actimove, Cutimed, …
Full company profileEssity AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Essity AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 101B | 109B | 119B | 129B | 122B | 122B | 156B | 147B | 146B | 138B | 136B |
| Gross Profit | 28.3B | 31.9B | 32.0B | 37.9B | 39.4B | 35.1B | 37.2B | 44.5B | 47.1B | 46.1B | 43.4B |
| Operating Income | 9.01B | 11.9B | 10.8B | 14.3B | 16.8B | 13.2B | 9.48B | 15.1B | 18.3B | 18.5B | 16.0B |
| EBITDA | 14.0B | 18.0B | 17.5B | 21.9B | 24.5B | 17.2B | 17.6B | 24.4B | 26.1B | 25.7B | 23.3B |
| Net Income | 3.80B | 8.12B | 7.89B | 9.22B | 10.2B | 8.62B | 5.57B | 9.55B | 20.9B | 12.7B | 10.4B |
| EPS | 5.41 | 12 | 11 | 13 | 15 | 12 | 7.93 | 14 | 30 | 18 | 15 |
| Balance Sheet | |||||||||||
| Total Assets | 114B | 147B | 154B | 162B | 155B | 175B | 211B | 203B | 185B | 167B | 186B |
| Total Liabilities | 74.7B | 97.4B | 99.4B | 99.5B | 91.3B | 107B | 134B | 124B | 96.5B | 81.1B | 87.7B |
| Shareholders' Equity | 33.2B | 42.3B | 47.1B | 54.1B | 54.4B | 59.9B | 67.3B | 70.8B | 88.3B | 85.6B | 97.6B |
| Cash & Short-term Investments | 4.26B | 4.13B | 3.03B | 3.08B | 5.15B | 4.09B | 7.75B | 8.66B | 15.6B | 9.33B | 6.59B |
| Total Debt | 35.4B | 53.9B | 53.4B | 51.0B | 45.9B | 58.2B | 71.5B | 55.8B | 43.8B | 37.2B | 39.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.8B | 12.7B | 13.2B | 19.4B | 17.8B | 14.7B | 12.9B | 21.6B | 16.8B | 15.5B | 17.1B |
| Capital Expenditure | 6.34B | 6.16B | 6.91B | 5.95B | 6.61B | 7.36B | 6.95B | 6.89B | 7.44B | 7.09B | 5.65B |
| Free Cash Flow | 6.44B | 6.57B | 6.25B | 13.4B | 11.2B | 7.31B | 5.93B | 14.7B | 9.37B | 8.37B | 11.5B |
| Ratios | |||||||||||
| ROE | 11.4% | 19.2% | 16.7% | 17.0% | 18.8% | 14.4% | 8.3% | 13.5% | 23.7% | 14.8% | 10.6% |
| ROA | 3.3% | 5.5% | 5.1% | 5.7% | 6.6% | 4.9% | 2.6% | 4.7% | 11.3% | 7.6% | 5.6% |
| Net Profit Margin | 3.8% | 7.4% | 6.7% | 7.1% | 8.4% | 7.1% | 3.6% | 6.5% | 14.4% | 9.1% | 7.6% |
| Debt to Equity | 1.07x | 1.27x | 1.13x | 0.94x | 0.84x | 0.97x | 1.06x | 0.79x | 0.50x | 0.43x | 0.40x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Essity AB (publ) dividends
- Dividend yield
- 3.34%
- Forward dividend
- 0.93 USD
- Payout ratio
- 45.1%
- Ex-dividend date
- Mar 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SEK 5.71B | 8.29 | 45.1% |
| 2024 | SEK 5.44B | 7.77 | 26.1% |
| 2023 | USD 5.09B | 7.25 | 53.3% |
| 2022 | SEK 4.92B | 7.00 | 88.3% |
| 2021 | USD 4.74B | 6.75 | 55.0% |
| 2020 | USD 4.39B | 6.25 | 42.9% |
| 2019 | USD 4.04B | 5.75 | 43.8% |
| 2018 | USD 4.04B | 5.75 | 51.2% |
| 2017 | USD 4.04B | 5.75 | 49.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Essity AB (publ)
- Insiders 8.89%
- Institutions 54.02%
- Public & others 37.09%
- Shares outstanding 619M
- Free float 554M
Essity AB (publ) company profile
- Company name
- Essity AB (publ)
- Ticker
- ETTYF.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 36,000
- Fiscal year end
- December
- Address
- Klarabergsviadukten 63, Stockholm, Sweden, 101 23
- Phone
- 46 87 88 51 00
- Website
- essity.com
About Essity AB (publ)
Essity AB (publ) develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally. The company operates through three segments: Health & Medical, Consumer Goods, and Professional Hygiene. The Health & Medical segment offers incontinence products, wound care, compression therapy, orthopedics, skincare products, and digital solutions with sensor technology under the TENA, Leukoplast, JOBST, Actimove, Cutimed, Delta-Cast, AquaCast Liner, and Hydrofera brands to family carers, professional caregivers, and patients and consumers through pharmacies, medical device stores, hospitals, distributors, care institutions, and e-commerce. The Consumer Goods segment provides pads, panty liners, tampons, diapers, wet wipes, shampoos, lotions, baby oil, skin creams, intimate soaps, intimate wipes, leakproof apparel, menstrual cups, toilet papers, household towels, handkerchiefs, facial tissues, and napkins under the TENA, Knix, Modibodi, Libero, Lotus, Libresse, Bodyform, Nana, Saba, Nosotras, TOM Organic, Tempo, Zewa, Cushelle, Plenty, Regio, and Familia brands through retail trade and e-commerce. The Professional Hygiene segment offers toilet papers, paper hand towels, napkins, hand soaps, hand lotions, hand sanitizers, dispensers, and cleaning and wiping products, as well as vision cleaning and data-driven cleaning solutions under the Tork brand to companies and office buildings, universities, healthcare facilities, airports, industries, restaurants, hotels, stadiums, and other public venues through direct to the end-customer, e-commerce, or distributors. Essity AB (publ) was founded in 1849 and is headquartered in Stockholm, Sweden.
Essity AB (publ) management
10- Ms. Ulrika Kolsrud MSc Eng.President & CEO · born 1970
- Mr. Carl Fredrik Stenson Rystedt B.Sc., MSc Econ.CFO, Executive VP of Central Function Finance · born 1963
- Mr. Niklas Westin SundbergChief Digital & Information Officer
- Ms. Sandra ÅbergVP & Head of Investor Relations
- Mr. Mikael SchmidtCLO, General Counsel, Secretary of the Board & Central Function of Legal Affairs and Compliance · born 1960
- Ms. Jessica AlmChief Communication Officer & Central Function of Corporate Communications · born 1977
- Ms. Anna Savinger-Åslund B.Sc.Chief Human Resources Officer & Central Function Human Resources · born 1969
- Mr. Volker Zoller B.A., B.Sc.President of Business Unit Consumer Tissue · born 1967
- Mr. Pablo Fuentes M.B.A., M.Sc.President of Business Unit Professional Hygiene · born 1973
- Mr. Tuomas Yrjölä B.A., M.Sc.President of Business Unit Personal Care · born 1978